Search

Author/Creator Simonelli, M.

1. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022)

Authors:
Di Giacomo, A.M.; Santangelo, F.; Amato, G.; E. Simonetti, ; Graham, J.; Lahn, M.; van der Veen, L.; Hammett, T.; Pickering, C.A.; Durini, M.; Ziyang, T.; Lakshmikanth, T.; Brodin, P.; Occhipinti, M.; Simonelli, M.; Carlo-Stella, C.; Santoro, A.; Spiliopoulou, P.; Evans, T.R.J.; Maio, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. (December 2022)

Authors:
Simonelli, M.; Calvo, E.; Davar, D.; Richards, D.; Gutierrez, M.; Moreno Garcia, V.; Marron, T.; Rottey, S.; Orcurto, A.; Renouf, D.J.; Joerger, M.; Barriga Falcon, S.; Fan, J.; Gibson, E.; Chakraborty, D.; Arora, V.; Melero, I.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. Issue 3 (September 2015)

Authors:
Ott, P.A.; Piha-Paul, S.A.; Munster, P.; Pishvaian, M.J.; Van Brummelen, E.; Cohen, R.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; Yuan, S.S.; Koshiji, M.; Bennouna, J.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
S102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗